TD Asset Management Inc Decreases Holdings in CRISPR Therapeutics AG $CRSP

TD Asset Management Inc decreased its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 5.7% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 228,416 shares of the company's stock after selling 13,904 shares during the period. TD Asset Management Inc owned 0.26% of CRISPR Therapeutics worth $11,110,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of CRSP. GAMMA Investing LLC lifted its position in CRISPR Therapeutics by 8,146.2% during the first quarter. GAMMA Investing LLC now owns 4,288 shares of the company's stock valued at $146,000 after acquiring an additional 4,236 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in CRISPR Therapeutics by 244.5% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 94,100 shares of the company's stock valued at $3,202,000 after purchasing an additional 66,789 shares in the last quarter. Janney Montgomery Scott LLC increased its stake in CRISPR Therapeutics by 55.7% during the 1st quarter. Janney Montgomery Scott LLC now owns 10,703 shares of the company's stock valued at $364,000 after purchasing an additional 3,827 shares in the last quarter. Sowell Financial Services LLC increased its stake in CRISPR Therapeutics by 8.4% during the 1st quarter. Sowell Financial Services LLC now owns 11,554 shares of the company's stock valued at $393,000 after purchasing an additional 900 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. increased its stake in CRISPR Therapeutics by 14.3% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 39,189 shares of the company's stock valued at $1,334,000 after purchasing an additional 4,914 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company's stock.

Insiders Place Their Bets

In other news, CEO Samarth Kulkarni sold 4,242 shares of the stock in a transaction on Tuesday, October 14th. The shares were sold at an average price of $66.60, for a total value of $282,517.20. Following the sale, the chief executive officer owned 205,096 shares in the company, valued at $13,659,393.60. This represents a 2.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel James R. Kasinger sold 1,076 shares of the stock in a transaction on Tuesday, October 14th. The stock was sold at an average price of $66.60, for a total transaction of $71,661.60. Following the sale, the general counsel directly owned 83,402 shares in the company, valued at $5,554,573.20. This trade represents a 1.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.30% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

CRSP has been the topic of a number of recent analyst reports. Wells Fargo & Company set a $75.00 price target on shares of CRISPR Therapeutics in a research note on Monday, October 13th. Zacks Research upgraded shares of CRISPR Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 26th. Royal Bank Of Canada upped their price target on shares of CRISPR Therapeutics from $38.00 to $42.00 and gave the company a "sector perform" rating in a research note on Tuesday, August 5th. JMP Securities restated a "market outperform" rating and set a $86.00 price target on shares of CRISPR Therapeutics in a research note on Friday, June 27th. Finally, Barclays upped their price target on shares of CRISPR Therapeutics from $42.00 to $56.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 6th. Ten analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat, CRISPR Therapeutics currently has a consensus rating of "Hold" and a consensus price target of $72.59.

CRISPR Therapeutics Price Performance

NASDAQ:CRSP opened at $69.15 on Friday. The firm has a market capitalization of $6.29 billion, a P/E ratio of -12.73 and a beta of 1.84. CRISPR Therapeutics AG has a 1-year low of $30.04 and a 1-year high of $78.48. The company's fifty day moving average price is $60.44 and its 200-day moving average price is $50.11.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The company reported ($1.29) earnings per share for the quarter, topping analysts' consensus estimates of ($1.47) by $0.18. The firm had revenue of $0.89 million for the quarter, compared to analyst estimates of $6.44 million. CRISPR Therapeutics had a negative net margin of 1,229.43% and a negative return on equity of 20.05%. The business's quarterly revenue was up 72.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.49) earnings per share. Equities analysts anticipate that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.